Establishment Labs (NASDAQ:ESTA – Get Free Report) and Cencora (NYSE:COR – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.
Insider & Institutional Ownership
72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 97.5% of Cencora shares are owned by institutional investors. 11.1% of Establishment Labs shares are owned by company insiders. Comparatively, 10.8% of Cencora shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Establishment Labs has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Cencora has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Establishment Labs | 1 | 1 | 6 | 0 | 2.63 |
| Cencora | 0 | 3 | 9 | 0 | 2.75 |
Establishment Labs currently has a consensus price target of $68.29, indicating a potential downside of 1.24%. Cencora has a consensus price target of $371.09, indicating a potential downside of 0.24%. Given Cencora’s stronger consensus rating and higher probable upside, analysts clearly believe Cencora is more favorable than Establishment Labs.
Valuation and Earnings
This table compares Establishment Labs and Cencora”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Establishment Labs | $190.97 million | 10.52 | -$84.60 million | ($2.84) | -24.35 |
| Cencora | $638.56 million | 112.94 | $1.51 billion | $7.95 | 46.79 |
Cencora has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Establishment Labs and Cencora’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Establishment Labs | -43.45% | -235.45% | -22.83% |
| Cencora | 0.60% | 267.36% | 4.31% |
Summary
Cencora beats Establishment Labs on 12 of the 14 factors compared between the two stocks.
About Establishment Labs
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
